22UA:FRA
BioNTech SE - ADR
€ ७९.६०
arrow_upward
+०.६३%(+०.५०) 1D
अक्टोबर १५, २२:००:०० GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€ ७८.६५
High
€ ७९.७०
Low
€ ७८.६०
Mkt. cap
२२.६६ अरब
Avg. vol.
१.४१ हजार
Volume
५२.००
52-wk high
€ १०५.५०
52-wk low
€ ६८.००
No. of employees
८ हजार
Open
€ ७८.६५
High
€ ७९.७०
Low
€ ७८.६०
Mkt. cap
२२.६६ अरब
Avg. vol.
१.४१ हजार
Volume
५२.००
52-wk high
€ १०५.५०
52-wk low
€ ६८.००
No. of employees
८ हजार
News stories
From web sources and news partners
ad-hoc-news.de
·
१२ घण्टा पहिले
Canaccord cuts target for BioNTech stock to USD 132.00
Pluang
·
१ दिन पहिले
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
१ दिन पहिले
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TipRanks
·
२ दिन पहिले
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR